Design, synthesis and SAR of phenylamino-substituted 5,11-dihydro-dibenzo[a,d]cyclohepten-10-ones and 11H-dibenzo[b,f]oxepin-10-ones as p38 MAP kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 10, 2010, Pages 3074-3077

  Dorn, Angelika ^a   Schattel, Verena ^a   Laufer, Stefan ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Kinase inhibitors; Linear binders

Indexed keywords

11H DIBENZO[B,F]OXEPIN 10 ONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PHENYLAMINO SUBSTITUTED 5,11 DIHYDRODIBENZO[A,D]CYCLOHEPTEN 10 ONE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; COMPETITIVE INHIBITION; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; STRUCTURE ACTIVITY RELATION;

ANTI-INFLAMMATORY AGENTS; BINDING SITES; COMPUTER SIMULATION; CYCLOHEPTANES; DRUG DESIGN; INTERLEUKIN-1BETA; OXEPINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77952108879     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.03.107     Document Type: Article

References (18)

1. Kumar S., Boehm J., and Lee J.C. Nat. Rev. Drug Disc. 2 (2003) 717
2. Lee J.C., Laydon J.T., McDonnell P.C., Gallagher T.F., Kumar S., Green D., McNulty D., Blumenthal M.J., Heys J.R., and Landvatter S.W. Nature 372 (1994) 739
3. Lee M.R., and Dominguez C. Curr. Med. Chem. 12 (2005) 2979
4. Feldmann M., Brennan F.M., and Maini R.N. Cell 85 (1996) 307
5. Feldmann M. Nat. Immunol. 2 (2001) 771
6. Laufer S.A., Ahrens G.M., Karcher S.C., Hering J.S., and Niess R. J. Med. Chem. 49 (2006) 7912
7. Laufer, S. Patent WO/2006/120010, 2006.
8. Schrödinger Suite 2008 Induced fit Docking protocol; Glide version 5.0, Schrödinger, LLC, New York, NY; Prime version 1.7, 2005.
9. LigPrep, version 2.2, Schrödinger, LLC, New York, NY, 2005.
10. Backes A.C., Zech B., Felber B., Klebl B., and Müller G. Expert Opin. Drug Discovery 3 (2008) 1409
11. Bandgar B.P., Bettigeri S.V., and Phopase J. Tetrahedron Lett. 45 (2004) 6959
12. Chowdhury S., and Georghiou P.E. Tetrahedron Lett. 40 (1999) 7599
13. Nizamuddin S., Ghosal M., and Chaudhury D.N. J. Indian Chem. Soc. 42 (1965) 569
14. Ong H.H., Profitt J.A., Spaulding T.C., and Wilker J.C. J. Med. Chem. 22 (1979) 834
15. Ong H.H., Profitt J.A., Anderson V.B., Spaulding T.C., Wilker J.C., Geyer III H.M., and Kruse H. J. Med. Chem. 23 (1980) 494
16. Smits R.A., Lim H.D., Stegink B., Bakker R.A., de Esch I.J.P., and Leurs R. J. Med. Chem. 49 (2006) 4512
17. Laufer S., Thuma S., Peifer C., Greim C., Herweh Y., Albrecht A., and Dehner F. Anal. Biochem. 344 (2005) 135
18. http://www.proqinase.com/ (the assay was performed at 10 μM inhibitor-concentration; values <20% are considered as no relevant inhibition).